The bacterial cell surface

is different between the two serovars, as represented by various O:H:K antigens. Lipopolysaccharide differences (O antigen) allowed the classification of S. Typhimurium in serogroup B, while S. Typhi belongs to serogroup D. Only S. Typhimurium is capable of phase variation of its H antigen, by differential expression of two flagella subunits. The most important feature is undoubtedly the presence of a polysaccharidic capsule (K antigen) specific to S. Typhi, the Vi antigen. However, it is also interesting Dactolisib to note that some S. Typhi strains and S. Paratyphi A lack the Vi antigen, but both cause a disease very similar to S. Typhi in the human host (McClelland et al., 2004; Baker et al., 2005). Virulence factors can be secreted using the general secretion machinery of the bacteria or by specific systems, such as the T3SS used to inject proteins directly into the host. No major differences were observed in both T3SS (Fig. S1a,b), ABT-737 cell line but some of the effectors were missing in S. Typhi (Table S1). However, the T6SS included on

SPI-6 is probably inactivated in S. Typhi by the presence of pseudogenes. Some toxins were specific to S. Typhimurium, such as SpvB present on the virulence plasmid. On the other hand, the CdtB and ClyA toxins are only produced by S. Typhi. Interestingly, most of the genes involved in intestinal colonization identified in S. Typhimurium are inactivated in S. Typhi. These genes encode autotransporters MisL and ShdA, adhesin SiiE, secreted protein RatB, putative outer membrane protein SinH and Lpf fimbriae (Fig. 1), suggesting that they are not needed by S. Typhi in the human host. This particular divergence is further acknowledged when looking at some work involving vaccine development (DiPetrillo et al., 1999; Angelakopoulos & Hohmann, 2000; Hindle et al., 2002). Salmonella enterica serovar Typhimurium and S. Typhi live-attenuated vaccine strains, both www.selleck.co.jp/products/carfilzomib-pr-171.html modified with the same genetic deletions, did not show the same level of intestinal colonization when administered orally to human

volunteers. Prolonged bacterial shedding by the host was observed over time with S. Typhimurium, but not with S. Typhi. Thus, precautions must be taken when extrapolating the S. Typhimurium data to S. Typhi. Many clinical trials investigating novel S. Typhi vaccine strains harbouring mutations that render S. Typhimurium avirulent and immunogenic in mice led to disappointing results at the attenuation level when administered to humans (Hone et al., 1988; Tacket et al., 1992a, b). The completion of additional genome sequencing projects of other Salmonella serovars or strains will contribute considerably to our understanding of niche adaptation and bacterial evolution in general, as well as conceiving the molecular basis of epidemics and how new virulent strains emerge. However, the availability of whole-genome sequences of several strains of different S.